No Data
No Data
Retail Investors Who Have a Significant Stake Must Be Disappointed Along With Institutions After Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Market Cap Dropped by CN¥694m
Key Insights Henan Lingrui Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 45% of the business is held
Estimating The Intrinsic Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Henan Lingrui Pharmaceutical fair value estimate is CN¥24.31 Henan Lingrui Pharmaceutical's CN¥25.65 share price indicates it is trading at s
Henan Lingrui Pharmaceutical (600285.SH) plans to distribute a dividend of 0.8 yuan per share in 2023, with ex-rights and ex-dividends on June 20th.
Henan Lingrui Pharmaceutical (600285.SH) announced that the company's annual profit distribution plan for 2023 is to distribute RMB...per share.
If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the
Henan Lingrui Pharmaceutical Leads Three Key Dividend Stocks In China
Some directors and supervisors of Ling Rui Pharmaceutical (600285.SH) completed a shareholding reduction of 1861,000 shares
Ling Rui Pharmaceutical (600285.SH) announced that company director Wu Xizhen and supervisor Li Jin reduced their holdings of the company by a total of 18...
No Data